Market Access Impact EU5 [Haemophilia A] [Report Updated: 01062017] Prices from USD $5145

05:29 EDT 1 Jul 2017 | BioPortfolio Report Blog

Losing share to competitors? Understanding market barriers can help close the gap

Haemophilia A treatment is a highly competitive market in the EU5 countries, where market shares for several of the brands we surveyed are very close. Understanding the market barriers that prevent doctors from prescribing your brand is essential if you want to build a lasting competitive advantage.

Learn how 7 barriers affect your market share, see who you take share from, and who gets your lost share in Market Access Impact: Haemophilia A EU5.

Based on a survey of 150 haematologists, the report covers 9 major therapies from Bayer, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Shire, Swedish Orphan Biovitrum.

Top Takeaways

The barrier effect is split evenly: 4 of the surveyed brands lose share because of barriers, 4 others gain, and one brand breaks even.

Not all brands are widely prescribed: Most brands are prescribed by less than 70% of doctors. However, most doctors are willing to consider brands they don't prescribe.

One brand can't catch a break: The 4th place brand loses share to every other surveyed brand because of barriers.

Barriers affect the market equally: Each of the 7 surveyed barriers affects roughly the same number of prescriptions.

Barriers aren't a problem for all doctors all the time: For the most part, fewer than 20% of doctors experience any one barrier with a given brand.

Patient preferences are a huge problem for one brand: Nearly 20% of doctors experience cost barriers with this brand; 10% more than any competitor.

Insight into 9 Major Haemophilia A Drugs

Advate octocog alfa; Antihemophilic Factor [human]; Shire

Elocta efmoroctocog alfa; Swedish Orphan Biovitrum

Feiba AntiInhibitor Coagulant Complex; Shire

HaemateP Antihemophilic Factor/von Willebrand Factor Complex [human]; CSL Behring

Helixate NexGen octocog alfa; CSL Behring

Kogenate Bayer octocog alfa; Bayer

NovoEight turoctocog alfa; Novo Nordisk

Octanate purified factor VIII concentrate; Octapharma

ReFacto AF moroctocog alfa; Pfizer

Exploring Market Access Barriers

Market Access Impact: Haemophilia A EU5 explores key issues affecting drug manufacturers. You'll learn:

How barriers affect market access:

What brands do doctors prescribe the most?

How many prescriptions do barriers affect?

Which barriers have the biggest impact?

How barriers affect your brand:

How many doctors prescribe your brand? How many don't, but would consider it?

Why don't doctors prescribe your brand? What do they prescribe instead?

Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 medical haematologists30 from each EU5 country France, Italy, Germany, Spain, UKchosen from the largest community of validated physicians in the world.

All respondents have:

Been practicing for 2+ years

Prescribed at least one of the listed products

Seen at least 5 patients with haemophilia A in total in the last month

We conducted the survey between May 2nd and 10th, 2017.


At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering uptotheminute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, needtoknow intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Original Article: Market Access Impact EU5 [Haemophilia A] [Report Updated: 01062017] Prices from USD $5145


More From BioPortfolio on "Market Access Impact EU5 [Haemophilia A] [Report Updated: 01062017] Prices from USD $5145"

Quick Search


Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...